Atlas Trials

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Clinical trial NCT05530421 · RECRUITING

Trial details

NCT number
NCT05530421
Sponsor
University of Miami
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsed and Refractory Multiple Myeloma
Start date
2023-03-26
Primary completion
2028-03-26
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.